Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00800462 |
Recruitment Status :
Completed
First Posted : December 2, 2008
Last Update Posted : April 8, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Spinal Cord Injury Neurogenic Detrusor Overactivity | Drug: Oxybutynin Cl Drug: Trospium Cl Drug: Darifenacin Hydrogen Bromide (HBr) | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 23 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity |
Study Start Date : | March 2008 |
Actual Primary Completion Date : | June 2012 |
Actual Study Completion Date : | December 2012 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Oxybutynin Cl |
Drug: Oxybutynin Cl
15 mg qd for 3 months
Other Name: Uromax |
Active Comparator: Trospium Cl |
Drug: Trospium Cl
20mg bid for 3 months
Other Name: Trosec |
Active Comparator: Darifenacin Hydrogren Bromide (HBr) |
Drug: Darifenacin Hydrogen Bromide (HBr)
15 mg qd for 3 months
Other Name: Enablex |
- Frequency of Incontinence Episodes [ Time Frame: 3 days ]
- Adverse Event Reporting [ Time Frame: Each Study Visit and Follow-up Phone Call ]
- Urodynamic Study [ Time Frame: Baseline and 3 months ]
- Questionnaires [ Time Frame: Monthly ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Male or female patients, between 18 and 75 years of age. Female patients of childbearing potential* must have a negative urine pregnancy test result on the day of Screening Visit and practice a reliable method of contraception**
*A female is considered of childbearing potential unless she is:
- Postmenopausal for at least 12 months prior to study drug administration;
- Without a uterus and/or both ovaries; or
-
Has been surgically sterilized for at least 6 months prior to study drug administration.
**Reliable methods of contraception include:
- Hormonal methods or intrauterine device in use at least 30 days prior to study drug administration;
- Barrier methods plus spermicidal in use at least 14 days prior to study drug administration; or
- Sexual abstinence as a lifestyle.
-
Patients with a neurogenic bladder and detrusor overactivity secondary to a spinal cord injury.
- Patients with urinary incontinence (minimum of one occurrence per day) despite current treatment. [NOTE: Bladder emptying may be accomplished with straining, intermittent catheterization (IC), spontaneous micturition or leakage episodes.]
- Patients with serum creatinine within normal limits and normal renal function
- Patients on a stable dose (minimum one month) of concomitant medication for Neurogenic detrusor overactivity
- Patients must have adequate cognitive function to understand the requirements of the study, including completing questionnaires and signing a written Informed Consent.
Exclusion Criteria:
- Female patients who are pregnant (positive urine pregnancy test), planning to become pregnant during the study period, breast-feeding, or who are of childbearing potential and not practicing a reliable method of birth control.
- Patients with a history of transurethral sphincterotomy, bladder neck or prostatic resection, previous bladder surgery including myomectomy or augmentation cystoplasty.
- Patients with chronic indwelling catheters.
- Patients with, in the opinion of the Investigator, unstable or stable multiple sclerosis.
- Patients with known, uncontrolled systemic disease.
- Patients with evidence of recent alcohol/drug abuse.
- Patients with urinary retention, gastrointestinal obstructive disorders or uncontrolled narrow-angle glaucoma.
- Patients with contraindications to Trosec™, Enablex™ and Uromax®.
- Patients who, in the opinion of the Investigator, have a significant condition or situation that may put the patient at significant risk, confound the study results, or interfere significantly with the patient's participation in the study.
- Patients with a history of poor cooperation, non-compliance, or unreliability.
- Patients currently participating in an investigational drug study or who have participated in an investigational drug study within 30 days of the Screening Visit.
- Patients administered anticholinergics and/or antispasmodic drugs during the course of the study.
- Patient with hepatic insufficiency.
- Patient has been administered intravesical botulinum toxin within 6 months prior to the Screening Visit and/or is expected to receive intravesical botulinum toxin during the course of the study.
- Patient has any medical condition that would interfere with the interpretation of the study results or the conduct of the study.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00800462
Canada, Manitoba | |
University of Manitoba, Health Sciences Centre | |
Winnipeg, Manitoba, Canada, R3A1R9 | |
Canada, Ontario | |
Toronto Rehabilitation Institute, Lyndhurst Centre | |
Toronto, Ontario, Canada, M4G 3V9 |
Principal Investigator: | Magdy Hassouna, MD | Toronto Rehabilitation Institute |
Responsible Party: | Magdy Hassouna, MD PhD FRCSC FACS, Toronto Rehabilitation Institute |
ClinicalTrials.gov Identifier: | NCT00800462 |
Other Study ID Numbers: |
2007-SCI-M3-488 |
First Posted: | December 2, 2008 Key Record Dates |
Last Update Posted: | April 8, 2013 |
Last Verified: | April 2013 |
Spinal Cord Injuries Urinary Bladder, Overactive Spinal Cord Diseases Central Nervous System Diseases Nervous System Diseases Trauma, Nervous System Wounds and Injuries Urinary Bladder Diseases Urologic Diseases Lower Urinary Tract Symptoms Urological Manifestations Bromides Oxybutynin |
Darifenacin Anticonvulsants Parasympatholytics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Muscarinic Antagonists Cholinergic Antagonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Urological Agents |